Navigation Links
Watson Pharmaceuticals and Arrow Group Receive FTC Second Request
Date:8/6/2009

MORRISTOWN, N.J., Aug. 6 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today announced that it has received a request for additional information from the Federal Trade Commission ("FTC") in connection with Watson's pending acquisition of privately held Arrow Group. The information request was issued under notification requirements of the Hart.Scott.Rodino Antitrust Improvements Act of 1976, as amended ("HSR Act"). The effect of the second request is to extend the waiting period imposed by the HSR Act until 30 days after Watson and Arrow Group have substantially complied with the request, unless that period is extended voluntarily by the parties or terminated sooner by the FTC. Watson intends to cooperate fully with the FTC's review and continues to expect the transaction to close in the second half of 2009.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is a global leader in the development and distribution of pharmaceuticals with a broad portfolio of generic products and a specialized portfolio of brand pharmaceuticals focused on Urology, Women's Health and Nephrology/Medical.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement

Any statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Watson's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, the impact of competitive products and pricing; market acceptance of and continued demand for Watson's products; difficulties or delays in manufacturing; the difficulty of predicting the timing or outcome of FDA or other regulatory agency approvals or actions, if any; and other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's Quarterly Report on Form 10-Q for the period ended June 30, 2009.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO)


'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
2. Watson Wyatt Identifies Major Benefit Trends During Open Enrollment Season
3. Texas Affiliates of Susan G. Komen for the Cure, Sen. Kirk Watson, Rep. Patrick Rose, Singer Kelly Willis, Breast Cancer Survivors and Activists Rally for Passage of Proposition 15
4. Watson Files FDA Application for Generic YAZ(R)
5. Watson Names Mark Durand Chief Financial Officer
6. Watson and Novartis Settle Lawsuit Over Exelon(R) Patent Litigation
7. Barr Subsidiary Sues Watson and Sandoz for SEASONALE(R) Patent Infringement
8. Watson Confirms Patent Litigation With Barr Related to Seasonale(R)
9. Watson Receives FDA Approval for Generic DuoNeb(R)
10. Watson to Distribute Alendronate Tablets
11. Medical Cost Increases to Accelerate Worldwide Over Next Five Years, Watson Wyatt Poll Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... ... September 19, 2017 , ... Presenting ... Benefit Administrators (SPBA) hosted “Expanding Your Success” with an educational emphasis. , ... focused on best practices for third party administrators (TPAs) related to health plan ...
(Date:9/19/2017)... ... September 19, 2017 , ... The Semper Fi Fund, one of ... release of a series of videos and a compelling documentary that provide unique insights ... United States as part of its ongoing mission. , Each of the videos focuses ...
(Date:9/19/2017)... ... September 19, 2017 , ... Public outrage over the toxins ... fallen on deaf ears, leaving the water industry itself to research, develop and ultimately ... of the curve in the field of natural alkaline water technologies, ...
(Date:9/19/2017)... (PRWEB) , ... September 19, ... ... memory-enhancing and cognitive health supplement developed by a neurosurgeon, has received a ... retailers. , Daily Brain Booster is currently available on the Wal-Mart ...
(Date:9/19/2017)... TX (PRWEB) , ... September 19, 2017 , ... ... the United States, named Dr. Howard Ng, as the new Medical Director of its ... be the new facility Medical Director of our Pflugerville- FM 685 location,” said Dr. ...
Breaking Medicine News(10 mins):
(Date:9/12/2017)... , Sept. 12, 2017   EcoVadis , the leading platform for ... the first annual edition of its Global CSR Risk and Performance Index. ... by EcoVadis, based on Scorecard Ratings that analyzed nearly 800,000 data points ... ... ...
(Date:9/12/2017)... FRANCISCO , Sept. 12, 2017  ValGenesis ... Management Solutions (VLMS), is pleased to announce the ... a member of its Board of Directors and ... ValGenesis VLMS enables life science companies to manage ... the use of paper in this process. Furthermore, ...
(Date:9/9/2017)... , Sept. 8, 2017 Dealmed Medical Supplies, ... supplier of medical equipment, supplies, drugs, vaccines, and specialty ... entered into an agreement to acquire Vantage Medical Supplies, ... in Holtsville, New York . ... supplying new and emerging medical practices, will operate under ...
Breaking Medicine Technology: